OpenAI CEO Sam Altman's decision to join President Trump's "Stargate" AI initiative marks a stark reversal for the tech CEO, ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

Parmy Olson is a Bloomberg Opinion columnist covering technology. A former reporter for the Wall Street Journal and Forbes, ...

Kevin Zhou's Sam Altman, published in November 2024, is a detailed portrait of the AI entrepreneur, from his early days as a ... ended up taking part. The biography offers contradictory views ...

was $540 now $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025.

The dispute between arguably the two biggest names in generative artificial intelligence—billionaires Sam Altman and Elon Musk—erupted this week after President Donald Trump announced a $500 ...

OpenAI chief Sam Altman has ... It's not the first time Altman and Musk have publicly sparred with each other online. The pair have a history that goes back to OpenAI's early days.

Sam Altman, CEO of OpenAI, has clarified that the company has not yet achieved Artificial General Intelligence (AGI), despite ...

The race to increase human life span through ... that’s set to enter an early-stage trial in Australia this year. Some of the investment will come from OpenAI CEO Sam Altman, who also provided ...

Kevin Zhou's Sam Altman, published in November 2024, is a detailed portrait of the AI entrepreneur, from his early days as a Stanford University ... so no Chinese firms ended up taking part. The ...